We investigated the effect of the administration of small doses of thyroxine to healthy humans and patients with type 2 diabetes on postprandial forearm muscle glucose uptake, insulin sensitivity indices, lipid metabolism, in vitro glucose uptake and GLUT4 recruitment in the plasma membrane of monocytes.
The present open-labeled, randomized and placebo-controlled study was undertaken in euthyroid type 2 diabetic patients and healthy humans, to examine the effect of administration of small doses of thyroxine within the euthyroid range, on muscle glucose disposal, postprandial insulin sensitivity, lipid metabolism, in vitro glucose uptake and GLUT4 recruitment in the plasma membrane of monocytes.This was investigated with the arteriovenous-difference technique after the consumption of a mixed meal and the in vitro study of a glucose analogue(6-NBDG) uptake by the peripheral monocytes. Subjects and Methods: Eleven euthyroid, treatment naive, type-2 diabetic patients with a micronodular texture of the thyroid gland and eleven healthy euthyroid subjects, were studied before and after administration of 50 μg of thyroxine once daily for 2 months. In parallel, a placebo group was also studied. Eleven euthyroid treatment-naïve subjects with type 2 diabetes and a micronodular texture of the thyroid gland, matched for age, sex, BMI, and basal thyroid function, were studied before and after administration of a placebo, once daily for 2 months. Experimental protocol: All subjects were admitted to the hospital at 0700 h after an overnight fast and had the radial artery (A) and a forearm deep vein (V) catheterized. A meal (730kcal, 50%carbohydrate, of which 38% was starch, 40% fat, and 10% protein) was given at least 1 h after catheter insertion and was consumed within 20 min. Blood samples were drawn from both sites before the meal (at -30 and 0 min) and at 30- to 60-min intervals for 300 min thereafter for measurements of thyroid hormones,glucose, total cholesterol, LDL Cholesterol, HDL Cholesterol, triglycerides, Apolipoprotein A1, Apolipoprotein BII and Lp(a).Forearm blood flow was measured with strain-gauge plethysmography. After the first meal tolerance test, treatment with 50μg of thyroxine or placebo, once daily, was initiated for a 2-month period. Then a second identical test was repeated. Special care was taken in order to avoid the induction of subclinical hyperthyroidism, that is suppression of TSH below 0.27 μU/ml, as it has recently been shown that the latter is also an insulin-resistant condition.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
33
area under the glucose uptake versus time curve-AUC
Muscle glucose uptake following meal ingestion
Time frame: Time Frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Plasma glucose levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Plasma insulin levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Plasma triglyceride levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Plasma total cholesterol levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Plasma LDL-cholesterol levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Plasma HDL-cholesterol levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Plasma Apo-A levels following meal ingestion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
area under the plasma concentration versus time curve-AUC
Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Plasma Apo-B levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Plasma Lp(α) levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Plasma NEFA levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Plasma glycerol levels following meal ingestion
area under the plasma concentration versus time curve-AUC
Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Muscle blood flow following meal ingestion
area under the plasma concentration versus time curve-AUC
Time frame: 0, 30, 60, 90, 120, 180, 240, 300 min postmeal
Plasma thyroid hormones
measure of plasma concentration
Time frame: baseline
glucose uptake by peripheral monocytes by the usage of the fluorescent analogue 6-NBDG
area under the curve of 6-NBDG uptake by monocytes under insulin stimulation
Time frame: baseline to 600 sec
% GLUT4 increment from baseline (0mU/l) to maximal concentration (200mU/l) of insulin.
Time frame: baseline
Number of participants with adverse events
Time frame: 300 min postmeal